Person who experienced the adverse event (patient)
| Event ID | CASE | I F COD | FOLL SEQ | IMAGE | EVENT DT | MFR DT | FDA DT | REPT COD | MFR NUM | MFR SNDR | AGE | AGE COD | GNDR COD | E SUB | WT | WT COD | REPT DT | OCCP COD | DEATH DT | TO MFR | CONFID | REPORTER COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7583764 | 8017037 | I | 7583764-8 | 20110510 | 20110618 | 20110630 | EXP | US-ROCHE-785548 | ROCHE | 70 | YR | F | Y | 74.9 | KG | 20110630 | MD | UNITED STATES |
Drug(s) used by person
| Event ID | DRUG SEQ | ROLE COD | DRUGNAME | VAL VBM | ROUTE | DOSE VBM | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7583764 | 1016905432 | SS | CISPLATIN | 1 | INTRAVENOUS | LAST ADMINISTERED ON 04 MAY 2011, TOTAL DOSE:180 MG, OVER 1 HOUR ON DAYS 1 AND 29 DURING RT | |||||
| 7583764 | 1016905431 | PS | BEVACIZUMAB | 2 | INTRAVENOUS | TOTAL DOSE: 1122 MG, LAST ADMINISTERED ON 04 MAY 2011, OVER 30-90 MINUTES ON DAYS 1, 15 AND 29 |
Indications of drugs used
| Event ID | DRUG SEQ | INDI PT |
|---|---|---|
| 7583764 | 1016905432 | ENDOMETRIAL CANCER |
| 7583764 | 1016905431 | ENDOMETRIAL CANCER |
Outcome of event
| Event ID | OUTC COD |
|---|---|
| 7583764 | LT |
Reactions reported
| Event ID | PT |
|---|---|
| 7583764 | LYMPHOCYTE COUNT DECREASED |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|
| 7583764 | 1016905432 | 20110406 | |||
| 7583764 | 1016905431 | 20110406 |